AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis

Fermenta Biotech reports 26% revenue growth in FY26

Enveric reports key safety milestone for EB-003 reinforcing clinical development path

The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors

Sun Pharma reports FY26 revenue of Rs. 58,220 crore, net profit at Rs. 11,479 crore

Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth

Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%

Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth

Amanta Healthcare reports 42% YoY growth in FY26 profit

The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25

Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%

Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth

Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives